Regulatory T cells (Tregs) are contributors of tumor immune evasion; Ikaros family zinc finger protein 2 (IKZF2) plays a crucial role in the maintenance of function and stability of Tregs. IKZF2-deificent tumoral Tregs produce inflammatory cytokines and enhance antitumoral immunity in mice.
Txinno Bioscience has presented benzotriazole derivatives acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (E-NPP 1) inhibitors reported to be useful for the treatment of cancer.
The Broad Institute, Janssen Biotech and Massachusetts General Hospital have divulged new serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
3T Biosciences Inc. raised $40 million in a series A funding round to take forward a platform for identifying novel T-cell receptors (TCR) and their targets, which is based on the work of scientific co-founder K. Christopher Garcia of Stanford University.
Shandong University scientists have evaluated structural modification of parbendazole to derive potential treatments for head and neck squamous cell carcinoma (HNSCC).
At the ongoing American Chemical Society meeting, Genentech detailed the discovery of KRAS G12C-selective covalent inhibitors for the potential treatment of cancer.
The Universite Catholique de Louvain has described polypeptides acting as lactate dehydrogenase (LDH) tetramerization inhibitors reported to be useful for the treatment of cancer.
Korea Research Institute of Chemical Technology (KRICT) and PINOTBIO have patented benzothiazole and benzimidazole derivatives acting as NAD-dependent protein deacetylase sirtuin-7 (SIRT7) inhibitors reported to be useful for the treatment of cancer, among other disorders.
Nuvectis Pharma Inc. has been in business for barely two years, but thanks to a business model involving in-licensing promising late preclinical drug candidates, it has already begun a trial with a molecule targeting a little-known pathway that cancer cells depend on for protection. The firm is also close to the clinic with a drug that could give a new twist to tyrosine kinase inhibition after a $16 million financing round in early August.
RSS
